What medicine is Barigen 4mg?
What medicine is Barigen 4mg?
Blog Article
Rheumatoid arthritis is a chronic inflammatory autoimmune disease that affects approximately 1.5 million people in the United States and is nearly three times more common in women than in men. Rheumatoid arthritis affects the lining or synovial membrane of the joints, causing painful swelling and can lead to rheumatoid arthritis. bone erosion and deformity. Other organs affected by the disease include the skin, eyes, lungs, heart, kidneys, and nerve tissue. In addition, patients with rheumatoid arthritis are at increased risk of cardiovascular disease.
Rheumatoid arthritis is associated with body pain, impaired physical function and low energy levels, thus profoundly affecting the patient's quality of life.
Treatment of rheumatoid arthritis aims to reduce inflammation, relieve symptoms, prevent joint and organ damage, and improve the patient's function and health.
Drug treatments for rheumatoid arthritis include nonsteroidal anti-inflammatory drugs; corticosteroids; conventional disease-modifying antirheumatic drugs (DMARDs); biologic response modifiers, a more recent group of DMARDs that includes tumor necrosis factor (TNF) inhibitor biologics and non-TNF biologics; and Janus kinase (JAK) inhibitors.
Barigen 4 mg (Baricitinib) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an inadequate response to or are intolerant to one or more disease-modifying antirheumatic drugs.
Barigen 4mg can be used as monotherapy or in combination with methotrexate.
Drug information
Ingredients: Baricitinib 4mg.
Dosage form, route of administration: Tablets, Oral.
Specification: Box of 30 tablets..
Manufacturer: General – India.
What is the effect of Barigen 4mg? Mechanism of action?
Baricitinib is an orally administered, selective and reversible inhibitor of Janus Kinases (JAKs). Janus Kinases are intracellular enzymes that belong to the tyrosine-protein kinase family and regulate signaling from cytokines and growth factor receptors involved in immune cell function.
There are four JAK proteins (JAK 1, JAK 2, JAK 3, and TYK2). These proteins bind differently at different cell receptors and form homodimers or heterodimers. These JAK dimers phosphorylate transcription (STAT) proteins and activate the intracellular activity, including gene transcription, of inflammatory mediators that lead to autoimmune responses.
Baricitinib has a higher affinity for JAK1 and JAK2. It inhibits JAK proteins, prevents phosphorylation and activation of STATs, and modulates the signaling pathways of multiple interleukins, interferons, and growth factors. Baricitinib also reduces proliferation and expression of JAK1/JAK2 in mutant cells and induces cell apoptosis.
Uses of Barigen 4mg
Barigen 4mg is a disease-modifying antirheumatic drug (DMARD) and is FDA-approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs), including TNF antagonist therapy.
Off-label use: Based on a clinical trial in 2020, the FDA granted emergency use authorization for baricitinib in combination with remdesivir to treat COVID-19 in hospitalized patients requiring invasive mechanical ventilation with supplemental oxygen or extracorporeal membrane oxygenation (ECMO). Baricitinib is not FDA-approved as a stand-alone treatment for COVID-19.
Future Use: A clinical trial (BREEZE-AD7) has demonstrated the efficacy of baricitinib and topical corticosteroids in improving the signs and symptoms of severe atopic dermatitis. It is currently under review for approval by the FDA. Similarly, clinical trials have shown promising results for baricitinib in the treatment of alopecia areata.
Contraindications
Patients with serious systemic or local infections, including hepatitis, HIV, or fungal infections, should avoid using this medicine until the active infection has been fully treated. It should not be used in patients with active tuberculosis.
Barigen 4mg is contraindicated in patients with chronic kidney disease with a GFR below 30 mL/min/1.73 m^2. It is not recommended in patients with severe hepatic impairment.
Patients with significant anemia with hemoglobin less than 8 mg/dL, lymphopenia with absolute lymphocyte count (ALC) less than 500 cells/mm^3, or neutropenia with absolute neutrophil count (ANC) less than 1,000 cells/mm^3 should avoid Baricitinib until the disease-free count is restored.
Baricitinib should not be used in combination with disease-modifying biologic antirheumatic drugs. Due to the lack of clinical data on pregnancy and lactation in humans, use of this drug during pregnancy and lactation should be avoided. Female patients of childbearing potential should use effective contraception and should inform their clinician if they become pregnant.
Dosage and how to use Barigen 4mg
The recommended dose for rheumatoid arthritis is 2 mg orally daily and in COVID-19 infection, oral baricitinib 2 mg has been evaluated in clinical trials with antiviral therapy for 10 to 14 days.
Dosage adjustment in renal disease
– CrCl 60 to less than 90 mL/min: No adjustment is recommended.
– CrCl less than 60 mL/min: Not recommended.
Dosage adjustment for liver disease
– Mild to moderate liver impairment: No adjustment is recommended.
– Severe liver failure: Should not be used.
Side effects of Barigen 4mg
Baricitinib is generally considered safe and well tolerated, but it may increase the risk of serious infections because it is an immunosuppressant. The most common infections are upper respiratory tract and urinary tract infections, but the incidence of herpes zoster has also been increased. Opportunistic infections include tuberculosis, histoplasmosis, pneumocystosis, candidiasis, BK virus infection, and cytomegalovirus infection.
Baricitinib has been associated with bone marrow suppression and hematologic abnormalities, including anemia, leukopenia, and lymphopenia, and requires frequent laboratory monitoring. Another side effect commonly observed after 12 weeks of baricitinib use was an increase in mean cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels without an increase in the LDL to HDL ratio. An increase in CPK levels has also been observed in some patients.
Deep vein thrombosis and pulmonary embolism have also been observed in clinical trials and postmarketing surveillance. A small percentage of patients also developed malignancies, including lymphoma and melanoma.
Among gastrointestinal side effects, nausea, vomiting, and abdominal pain are commonly reported. However, serious side effects such as gastrointestinal perforation are rare but have been reported in patients with a history of diverticulitis. Transient elevations in liver enzymes have been observed with baricitinib compared with placebo.
The use of Baricitinib in human pregnancy has not been well studied. According to clinical data in animal studies, baricitinib has been associated with low birth weight and teratogenicity. Baricitinib has been found to be excreted in rat milk in experiments; there are no data on its presence in human milk, therefore use in nursing mothers should be avoided. Similarly, animal studies have shown adverse effects of baricitinib on female fertility without any specific effects on male spermatogenesis.
Phone: +8801933042721
Email: iebpharma108@gmail.com
Sector 3, Road 8, Uttara-1230 Dhaka, Bangladesh
website: https://iebpharma.com